iCure Submits IND Application for Donepezil Patch Phase 1 Trial to US FDA
[Asia Economy Reporter Park Jihwan] iCure announced on the 31st that it has submitted an Investigational New Drug (IND) application for the Phase 1 clinical trial of donepezil patch to the U.S. Food and Drug Administration (FDA). The target disease is Alzheimer's disease.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This clinical trial aims to evaluate the steady-state pharmacokinetics of the 'IPI-401' patch administered transdermally twice a week and 'Aricept' tablets administered orally once daily in healthy adults.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
